200 - 3650 GILMORE WAY, BURNABY, A1
Approval of 2026 Equity Incentive Plan at Xenon Pharmaceuticals Annual Meeting
Reports Q1 2026 Financial Results and Provides Business Update
Annual Report to Security Holders
Xenon Pharmaceuticals Increases Share Reserve Under 2025 Inducement Plan
Announces Annual Meeting of Shareholders
Xenon Pharmaceuticals Enters Underwriting Agreement for Public Offering
Investor Presentation
Xenon Pharmaceuticals Files $400 Million Prospectus Supplement
Q1
FY 2024
Q3
Q2
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
S-8 POS